Naltrexone: A Cornerstone in Medication-Assisted Treatment
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $7.16 | $214.69 (0%) | 🛒 Add to cart |
| 60 | $6.77 | $429.37 $406.30 (5%) | 🛒 Add to cart |
| 90 | $6.63
Best per pill | $644.06 $596.91 (7%) | 🛒 Add to cart |
Synonyms | |||
Naltrexone is a potent opioid antagonist medication primarily indicated for the management of alcohol use disorder and the prevention of relapse to opioid dependence following detoxification. It functions by competitively binding to opioid receptors in the brain, effectively blocking the euphoric and sedative effects of opioids and reducing the craving for alcohol. Available in both oral tablet and extended-release intramuscular injectable formulations, naltrexone represents a critical pharmacological tool in comprehensive addiction treatment protocols. Its efficacy is significantly enhanced when integrated with a full spectrum of behavioral interventions and counseling, supporting long-term recovery goals.
Features
- Pharmacological Class: Pure opioid antagonist.
- Available Formulations: 50 mg oral tablets and 380 mg extended-release injectable suspension (Vivitrol®).
- Mechanism of Action: Competitive binding at mu-opioid receptors.
- Bioavailability: Oral: 5–40% (extensive first-pass metabolism); Injectable: Provides sustained release over approximately 4 weeks.
- Half-life: Oral: 4 hours (but active metabolite, 6-β-naltrexol, has a 13-hour half-life); Injectable: Released over weeks.
- Metabolism: Primarily hepatic, via dihydrodiol dehydrogenase.
- Excretion: Primarily renal.
Benefits
- Blocks Opioid Effects: Prevents the euphoric and analgesic high associated with opioid use, removing the primary reinforcement for continued abuse.
- Reduces Alcohol Cravings: Modulates the brain’s reward system, leading to a significant decrease in the urge to consume alcohol and helping to maintain abstinence.
- Supports Long-Term Sobriety: The monthly injectable formulation ensures consistent medication coverage, eliminating the need for daily dosing and improving adherence.
- Non-Addictive and Non-Narcotic: As an antagonist, naltrexone has no abuse potential, diversion risk, or associated withdrawal syndrome upon discontinuation.
- Facilitates Psychosocial Therapy: By managing the biological drivers of addiction, it allows patients to more fully engage in and benefit from counseling and behavioral therapies.
- Flexible Dosing Options: Availability in daily oral and monthly injectable forms allows for treatment plans to be tailored to individual patient needs and lifestyles.
Common use
Naltrexone is FDA-approved for two primary indications. First, it is used for the treatment of alcohol use disorder (AUD) to reduce heavy drinking and support abstinence. It is most effective in motivated patients who have already achieved initial abstinence. Second, it is used for the prevention of relapse to opioid dependence in patients who have undergone complete opioid detoxification. It is crucial that a patient is fully opioid-free before initiation to avoid precipitating acute withdrawal. Off-label, naltrexone is sometimes used at lower doses (Low-Dose Naltrexone or LDN) for investigational purposes in conditions like fibromyalgia and certain autoimmune diseases, though robust evidence for these uses is still developing.
Dosage and direction
For Alcohol Dependence:
- Oral: The recommended dose is 50 mg once daily. Some protocols may utilize a reduced schedule (e.g., 100 mg every other day or 150 mg every third day) to improve adherence, though daily dosing is standard.
- Injectable (Vivitrol®): 380 mg delivered via intramuscular gluteal injection every 4 weeks or once monthly.
For Opioid Dependence:
- Oral: Treatment should not be initiated until the patient is opioid-free for a minimum of 7-10 days. A starting dose of 25 mg may be administered to assess for withdrawal precipitation. If no signs of withdrawal occur, the dose is increased to 50 mg once daily thereafter.
- Injectable (Vivitrol®): 380 mg IM injection every 4 weeks. Initiation must follow a minimum of 7–10 days of opioid abstinence.
Administration Notes:
- Oral tablets can be taken with or without food.
- The injectable formulation must be administered by a healthcare professional. It is provided as a kit requiring reconstitution prior to deep IM injection.
- Non-adherence to the oral formulation is a significant cause of treatment failure. The injectable form is often preferred for its guaranteed compliance over the dosing interval.
Precautions
- Opioid Abstinence Verification: The most critical precaution is ensuring the patient is opioid-free before starting naltrexone. A urine drug screen is mandatory. Administering a naloxone challenge test may be considered in cases where recent opioid use is suspected.
- Hepatotoxicity: Naltrexone has been associated with dose-related hepatocellular injury at high doses (>300 mg/day). While this is rare at standard therapeutic doses, baseline and periodic monitoring of liver function tests is advised, particularly in patients with pre-existing liver disease or acute hepatitis.
- Depression and Suicidality: As with many treatments for addiction, patients should be monitored for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior.
- Injection Site Reactions: The intramuscular injection can cause pain, tenderness, induration, swelling, erythema, bruising, or pruritus. Proper injection technique is essential to minimize these reactions.
- Pneumonia: Cases of eosinophilic pneumonia have been reported in patients receiving the injectable formulation.
Contraindications
- Current physical dependence on opioids or acute opioid withdrawal.
- Failure to pass a naloxone challenge test or a positive urine screen for opioids.
- Acute hepatitis or liver failure.
- Hypersensitivity to naltrexone or any component of the formulation (e.g., polylactide-co-glycolide microspheres in the injectable suspension).
Possible side effect
Common side effects are often transient and may include:
- Nausea, vomiting, abdominal pain, diarrhea
- Headache, dizziness, nervousness, insomnia
- Fatigue, anxiety
- Muscle or joint aches
- Injection site reactions (for Vivitrol®: pain, induration, swelling, erythema, bruising) Less common but more serious side effects require medical attention:
- Signs of hepatotoxicity (e.g., dark urine, jaundice, right upper quadrant pain)
- Severe depression or suicidal thoughts
- Signs of an allergic reaction (e.g., rash, hives, itching, difficulty breathing)
- Visual hallucinations or confusion (rare)
Drug interaction
- Opioid Analgesics: Naltrexone will block the effects of opioid pain medications, including those used for surgical analgesia, emergency trauma, or cough. Patients must be warned that they will not respond to standard doses of opioids. In an emergency, pain management requires higher doses of opioids under close supervision or the use of non-opioid analgesics or regional anesthesia.
- Opioid-Containing Medications: Naltrexone will also block the effects of opioid-containing medications, such as some antidiarrheal agents (e.g., Lomotil®) and certain cough suppressants.
- Thioridazine: Concurrent use has been reported to cause lethargy and somnolence.
Missed dose
- Oral Formulation: If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one.
- Injectable Formulation: The next injection should be administered as soon as possible by a healthcare professional.
Overdose
There is no clinical experience with naltrexone overdose in humans. In massive overdose, the primary risk would be related to its potent opioid-blocking effects, which could complicate pain management in an emergency setting. High doses have been linked to liver injury in animal studies. Management is supportive and symptomatic. Hemodialysis is not expected to be effective due to naltrexone’s large volume of distribution.
Storage
- Oral Tablets: Store at room temperature (20°–25°C or 68°–77°F) in a tight, light-resistant container. Keep out of reach of children.
- Injectable Suspension (Vivitrol®): The un-reconstituted kit should be refrigerated (2°–8°C or 36°–46°F). Do not freeze. After reconstitution, the suspension must be administered immediately. It cannot be stored.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author and publisher are not responsible for any specific health or allergy needs that may require medical supervision and are not liable for any damages or negative consequences from any treatment, action, application, or preparation, to any person reading or following the information in this document.
Reviews
- “As an addiction psychiatrist, naltrexone is a first-line tool in my arsenal. The injectable form, in particular, has been transformative for patients who struggle with daily pill adherence. It provides a ‘safety net’ that allows them to focus on their recovery work without the daily reminder of their disease.” – Dr. A., MD
- “After multiple failed attempts at sobriety from alcohol, my physician suggested Vivitrol. The reduction in cravings was noticeable within the first week. It didn’t magically cure my addiction, but it gave me the mental space to actually use the coping skills I learned in therapy. It was the key that unlocked my recovery.” – Patient J.S.
- “The requirement for 7-10 days of opioid abstinence prior to initiation remains a significant clinical hurdle. However, for those patients who successfully transition, naltrexone offers a safe and effective path to long-term recovery without substituting one opioid for another.” – Clinical Pharmacist, Addiction Medicine